XTL Biopharmaceuticals Ltd ADR

Company Profile

XTL Biopharmaceuticals Ltd ADR had its IPO on 2005-09-01 under the ticker symbol XTLB.

The company operates in the Healthcare sector and Biotechnology industry. XTL Biopharmaceuticals Ltd ADR has a staff strength of 0 employees.

Stock update

Shares of XTL Biopharmaceuticals Ltd ADR opened at $0.92 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.92 - $0.96, and closed at $0.96.

This is a +1.27% increase from the previous day's closing price.

A total volume of 403 shares were traded at the close of the day’s session.

In the last one week, shares of XTL Biopharmaceuticals Ltd ADR have slipped by -0.81%.

XTL Biopharmaceuticals Ltd ADR's Key Ratios

XTL Biopharmaceuticals Ltd ADR has a market cap of $5.18 million, indicating a price to book ratio of 1.4587 and a price to sales ratio of 0.

In the last 12-months XTL Biopharmaceuticals Ltd ADR’s revenue was $0 with a gross profit of $0 and an EBITDA of $-842000. The EBITDA ratio measures XTL Biopharmaceuticals Ltd ADR's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, XTL Biopharmaceuticals Ltd ADR’s operating margin was 0% while its return on assets stood at -12.2% with a return of equity of -68.88%.

In Q2, XTL Biopharmaceuticals Ltd ADR’s quarterly earnings growth was a negative -76% while revenue growth was a positive 0%.

XTL Biopharmaceuticals Ltd ADR’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

0

Its diluted EPS in the last 12-months stands at $-0.48 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into XTL Biopharmaceuticals Ltd ADR’s profitability.

XTL Biopharmaceuticals Ltd ADR stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.5778. Its price to sales ratio in the trailing 12-months stood at 0.

XTL Biopharmaceuticals Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$2.88 million

Total Liabilities

$163000.00

Operating Cash Flow

$0

Capital Expenditure

$0

Dividend Payout Ratio

0%

XTL Biopharmaceuticals Ltd ADR ended 2024 with $2.88 million in total assets and $0 in total liabilities. Its intangible assets were valued at $2.88 million while shareholder equity stood at $2.72 million.

XTL Biopharmaceuticals Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $163000.00 in other current liabilities, 14120000.00 in common stock, $-157748000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.59 million and cash and short-term investments were $2.38 million. The company’s total short-term debt was $0 while long-term debt stood at $0.

XTL Biopharmaceuticals Ltd ADR’s total current assets stands at $2.50 million while long-term investments were $0 and short-term investments were $794000.00. Its net receivables were $0 compared to accounts payable of $163000.00 and inventory worth $0.

In 2024, XTL Biopharmaceuticals Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $0.

Comparatively, XTL Biopharmaceuticals Ltd ADR paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.96

52-Week High

$1.54

52-Week Low

$0.75

Analyst Target Price

$

XTL Biopharmaceuticals Ltd ADR stock is currently trading at $0.96 per share. It touched a 52-week high of $1.54 and a 52-week low of $1.54. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.92 and 200-day moving average was $1.18 The short ratio stood at 0.22 indicating a short percent outstanding of 0%.

Around 1444.8% of the company’s stock are held by insiders while 458% are held by institutions.